Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinical Trial Enrollment

- PMLiVE

Lynparza could soon add first line ovarian use in Europe

Also first PARP inhibitor launched in China

It’s Complicated

Commercial executives should be more like their scientist colleagues

- PMLiVE

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Opioid dependence therapy and Pfizer's PARP inhibitor also recommended

AstraZeneca AZ

Oncology drives AstraZeneca, Genzyme boosts Sanofi

Specialist drugs are growth engines in Q1

- PMLiVE

Orphan drugs market to soar to $224bn by 2024

Cell and gene therapies to fuel growth

15 Personalized Medicine: It’s Time To Get Creative

Havas Lynx

14 Interpreting the Future of Healthcare

Havas Lynx

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

Artificial Intelligence: a new character in the storytelling of drug development and discovery?

Written by Edward Jones, Junior Medical Writer. Bedrock is dedicated to creating valuable and powerful stories to engage audiences that drive an improvement in the provision of health. This focus...

Bedrock Healthcare Communications

- PMLiVE

Post-merger Celgene to lead pharma growth

Moody’s predicts company will show most growth over next 18 months

- PMLiVE

Gilead’s NASH drug fails again

Drug failed to match results from placebo group

04 A Healthy Ambience

Creating a Lifeline to the New Digital User

Havas Lynx

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links